Member Info for Laura2022

You also

Hello

I asked about the biostatistics division, whether there might be a presentation at the time of the March results to expand on some of the items within the RNS and also whether we could perhaps reformulate contracts with a milestone payment element to it as some of PYC early stage assets have gone to be worth many multiples.

success of Numab Therapeutics' NM26 asset - an early clinical programme supported by Physiomics prior to being acquired by J&J for US$1.2 billion.

I was happy with the replies but legally cannot share sorry

Actions in 2025 will underpin positive free cash flow in 2026

· Positive free cash flow expected in 2026 (before disposals) reflecting:

o Continued improvements in operating cash flow6, which has improved from $(66) million in FY22 to c.$275 million in FY24, helped by working capital improvements, including the absence of the 2025 working capital unwind (c.$70 million)

o Growth in adjusted EBITDA and adjusted EBIT from underlying business growth

o Incremental benefit of cost savings in FY26 (c.$25 million)

o Reduction in cash exceptionals from c.$100 million in FY25 (consisting of asbestos, restructuring costs and advisor fees) to c.$40 million in FY26 (only asbestos)

· Note that legacy claims cash payments are expected to be broadly similar in FY25 and FY26 and will be reported separately to exceptional cash costs

All I can see is 100s of posts on PPP, SCGL, CLAI and lesser extent OBD CYK

"New uncle who was praised for their posts, now says PYC is a lifestyle company."

I can't find any of these posts that praised Newuncle, please could you re post

Thanks

Jaari888

Can you show where these "big sells" where as compared to big buys in the previous weeks...

Just to pick up on a few points

1 all AIM placings last 12mths have been, sadly somewhere between 50% and 20% discounted, that's the state of the markets , not sure if you knew that as you only post on PYC, as for Trout I don't recall any post about premium placing?

2 you say Clarets is a good egg.., not sure if he is good (or bad) as very rarely posted and they were just one liners, but sad to lose any investor I agree

3 how do we know Ant15 was the founder ?..he arrived mid last year claiming to be and saying mgmt didn't respond to him but we have nk evidence..his last post were October 2024 so not sure what valued insight he offered and his other shares TERN and CLON are heavily down so not sure his business accumen is to be lauded?

4 as for WRAP, as a holder you have the opportunity should you wish?

Depends whether you want to hold, add or sell

5 I have also emailed and got a reply this morning

Sad news Trench

And , as you say, puts some things into perspective

Also

1) the 2 peer reviews are significant

2) contracts are being discussed

3) personalised dosing tool is important

Clearly, the price and markets for raising money for small caps bio techs and resoirc stocks are difficult ( ONC PYC IMM and resource stocks like EME ROCK etc)

FAB did a heavily discounted fund raise but never looked back in late 2024

It probably got lost in the mud slinging early yesterday

This was from the recent PYC holder , hope he doesn't mind me posting it

Burt777

Posted in: PYC

Posts: 3

Price: 0.525

No Opinion

…13 Feb 2025 09:33

Just to add that they should be pleased to announce half a million quid on a tiny cap company. If they use that money to get this to a 10 million cap company for starters then people will look back at this and think it was smart. The fact they have raised more than last time is a good indication some believe in it.

But raising money for growth comes at a cost. They must think they can easily recoup the share price value and it’s in the best interest of shareholders to have good working capital while contracts are signed and progress continues.

Again this is AIM so you have to look at it pragmatically and optimistically.

100% gain can be done in a day on one small contract

So just ignore the SP today and suck it up or add

Sadly I won’t be adding but fully believe it will do at least 200% from here.

Patience is the name of the game.

Burt777

Posted in: PYC

Posts: 3

Price: 0.525

No Opinion

Placing13 Feb 2025 09:26

Good morning chaps breaking cover here as the major shareholder. Some people need to get a life this is an AIM company that has just essentially raised 25% of its market cap in funds to try and get somewhere. If they pull it off this will do 500%

A 200% gain is only a 4 million cap company.

It’s a tiny company so it’s done well to raise that money and sadly for me at least I’m diluted at this point.

But I am positive I’ll still make a lot of money here as it won’t take much good news to see me in profit. Hopefully future placing are done higher up to avoid dilution on the back of something significant.

Keeping the faith with this one and it’s a case of the old bottom draw.

Yes I’ve had a speculative investment but it’s money I could safely afford to lose. And I think many will do well to hold here in the long term but understand the disappointment of today. Nobody likes losing money ! Chin up and focus on the positives that the company has a 12 month runway to get into profitability.

Hopefully it does big gains from here !!

GLA and won’t be an active poster.

I might however be wrong

It stated:

The Directors have determined that, based on the base case forecast, the 80% threshold of the LTM revenue covenant will not be met and therefore the doubled level of the cash covenant will apply. Even though revenues continue to increase, they are not doing so at the pace required to meet the increased cash covenants. In this scenario, the Group will require further funding during the year. The Company is most likely to obtain these via financing process(es) involving current and/or new investors and/or a strategic collaboration. If any financing is sufficient to maintain liquidity but not to satisfy the cash covenants, temporary waivers would be sought with IPF (who, since the debt-for-equity transaction, are the largest shareholder), thereby giving the Group further runway to conclude strategic collaborations.

 

The plausible downside scenario would necessitate further increased inflows of funds and/or renegotiation with IPF.

 

Based on the above, the Directors have a reasonable expectation that the Group can continue to operate for the foreseeable future, however, there are material uncertainties relating to the quantum and timing of new order intake, the outcome of any financing processes and the outcome of any further renegotiation with IPF. For these reasons, the Directors acknowledge the existence of a material uncertainty which may cast significant doubt over the Group's and the Company's ability to continue in operation.

Think its linked to the paragraph in the last rns about funding discussion

According to telegram, can anyone confirm please as this write up makes ROQ look pretty undervalued

Updated 14:18, 10 Feb 2025By IAN LYALL AT PROACTIVE INVESTORS FOR THISISMONEY.CO.UK

Ajan Reginald, chief executive of Roquefort Therapeutics, has a knack for distilling complex strategies into a single sentence. 

‘We find diamonds in the rough and we cut and finish them,’ he says, summing up the company’s approach to biotech investment and development.

One example is the planned £8million sale of Lyramid, a business Roquefort acquired for just £1million. The simple arithmetic suggests a straightforward profit, but the real value lies in the work done in the interim.

Lyramid’s midkine inhibition assets (which offer a new approach to targeted cancer treatment) are now at what is known as the pre-investigational new drug stage.

In practical terms, pre-IND is the phase of drug research before human trials can begin. At this stage, scientists are working in the lab to establish how a drug functions, testing it on cells and animals to assess safety and efficacy.

Before regulators such as the US Food and Drug Administration (FDA) allow clinical trials, companies must demonstrate a clear understanding of how the drug works, provide robust data on its potential, and show that it can be manufactured safely and consistently.

With its midkine programme now at this point, Roquefort is preparing to sell Lyramid to Pleiades Pharma in a deal expected to complete by the end of June.

The agreement includes an upfront cash payment that will help fund Roquefort’s two remaining programmes, while also giving the company an equity stake in Pleiades. That exposure to a broader portfolio of drug assets—some already in clinical trials—could prove strategically valuable

Let's hope it's a more productive day rather than the vitriol of yesterday

Posting at 1 30am on a share you don't own , to tell lies and to spend 90% of your posts on a share you don't own but then spend no time on any meaningful other investments, and to have an LSE account which laid dormant for 5yrs+ until popping up solely on PYC

What a way to spend your life

Trading headlines

· Delivery of 2024 guidance supported by actions taken in Q4

o FY24 adjusted EBITDA1 of around $450 million to $460 million

o FY24 adjusted EBIT2 of c.$205 million to c.$215 million

o Actions taken to mitigate weaker-than-expected trading in Q4, including cancelling executive and employee bonuses and actively managing working capital at year end

o Completed sale of EthosEnergy for net cash proceeds of $138 million

o Net debt excluding leases at 31 December 2024 of around $690 million3 (31 December 2023: $694 million) and average net debt in 2024 of c.$1.1 billion

· Order book increased to c.$6.2 billion at 31 December 2024, significantly improved on c.$5.4 billion at 30 September 2024

o Large wins in Projects and Operations including bp, OMV Petrom and Esso Australia

o Improved order book underpins outlook for the business and long-term growth potential

Independent review ('Review')

· The Review is continuing and Deloitte's work and assessment will need to be complete before any conclusions can be reached. However, significant work has been undertaken and based on that:

o The Company does not expect that the findings of the Review will have a material impact on the Group's cash position or its ability to generate cash in the future

o Following provisional indications from the Review, the Company is evaluating the extent of prior year adjustments which the Company expects will be required in relation to the Projects business unit and their impact on previously reported adjusted EBITDA for FY23 and any prior periods

o The Company is initiating steps to strengthen significantly the Group's financial culture, governance and controls in light of material identified weaknesses and failures

There has been so many "first time "posts on here today you do wonder where these posters come from

You've never posted on PYC before yet claim to have sold

Yet have posted on BCE (Now bust?) COPL( suspended for 12mths ) etc

Some very strange posters today

Good luck solo

But it's alot different than COPL

Solo1

Posted in: COPL

Posts: 119

Price: 1.525

No Opinion

Daughters wedding fund18 Dec 2023 07:33

I sunk everything I had into this share a while ago, monies earned, and more. Whole daughters wedding fund, my only thing is I have a small bit of equity in my house but that won't cover it, she gets married in March, all has to be covered in 7 weeks time.

I can't tell her so I will just have to try and sort something, saving grace is when I go I have a couple of insurance policies. Aim has been a complete nightmare for me, its been like a drug with money I have had, and I believe people need help, I don't drink, smoke, do drugs, but have really been caught up over the years in so many bad shares, and these liars line there pockets and get away scott free.

Absolutely gutted, and I know there will be other people caught up in this. All I can say is Merry Xmas and hope no one does anything stupid.

Good by and good luck.

This was the best one

Porky9

Posted in: GDR

Posts: 7,266

Price: 2.675

No Opinion

Whooa30 Oct 2024 16:00

Only positive thing out of the budget:-

"She announces a £22.6bn increase in the day-to-day health budget, and £3.1bn increase in the capital budget. That includes £1bn for repairs and upgrades, and £1.5bn for new beds in hospitals and testing capacity"

Testing capability...... come to daddy....

So porky

What were these short positions?

This wasn't just another ramp was it ? Dear me

Porky9

Posted in: GDR

Posts: 7,266

Price: 2.375

No Opinion

RE: Pilot project details15 Nov 2024 11:29

Wonder which of those short posters here will crack first LoL. Last one to close their short takes a major bath when the update lands. Love it. More effort required boys, one last push?, it is Friday.

All being well we should get a likely update next week IMO it is due. Good luck